Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors
The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute to the development of solid tumors primarily through their effects on promoting uncontrolled cell proliferation. However, agents that antagonize the function of the protein products encoded by these (proto)-oncogenes are known to behave in vivo in a cytotoxic-like manner. This implies that such oncogenes may regulate critical cell survival functions, including angiogenesis. The latter could occur as a consequence of regulation of relevant growth factors by such oncogenes. We therefore sought to determine whether EGFR or ErbB2/neu may contribute to tumor angiogenesis by examining their effects on the expression of vascular endothelial cell growth factor (VEGF)/vascular permeability factor (VPF), one of the most important of all known inducers of tumor angiogenesis. We found that in vitro tre
%0 Journal Article
%1 Petit.1997
%A Petit, A. M.
%A Rak, J.
%A Hung, M. C.
%A Rockwell, P.
%A Goldstein, N.
%A Fendly, B.
%A Kerbel, R. S.
%D 1997
%J Am.J.Pathol.
%K A Adenocarcinoma Animals Antibodies Breast Carcinoma Cell Cells Cultured Dose-Response Down-Regulation Drug Endothelial Epidermal Expression Factor Factors Gene Growth Human Humans Immunoenzyme Lymphokines Mice Monoclonal Neoplasm Neoplasms Neoplastic Neovascularization Neutralization Nude Oncogenes Pathologic Proliferation Receptor Regulation Relationship Research Signal Squamous Survival Techniques Tests Transduction Transplantation Tumor Tyrosine Vascular blood cells drug effects erbB-2 immunology metabolism pathology pharmacology physiology protein therapy
%N 6
%P 1523-1530
%T Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors
%U PM:9403702
%V 151
%X The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute to the development of solid tumors primarily through their effects on promoting uncontrolled cell proliferation. However, agents that antagonize the function of the protein products encoded by these (proto)-oncogenes are known to behave in vivo in a cytotoxic-like manner. This implies that such oncogenes may regulate critical cell survival functions, including angiogenesis. The latter could occur as a consequence of regulation of relevant growth factors by such oncogenes. We therefore sought to determine whether EGFR or ErbB2/neu may contribute to tumor angiogenesis by examining their effects on the expression of vascular endothelial cell growth factor (VEGF)/vascular permeability factor (VPF), one of the most important of all known inducers of tumor angiogenesis. We found that in vitro tre
@article{Petit.1997,
abstract = {The overexpression in tumor cells of (proto)-oncogenic receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) or ErbB2/neu (also known as HER-2) is generally thought to contribute to the development of solid tumors primarily through their effects on promoting uncontrolled cell proliferation. However, agents that antagonize the function of the protein products encoded by these (proto)-oncogenes are known to behave in vivo in a cytotoxic-like manner. This implies that such oncogenes may regulate critical cell survival functions, including angiogenesis. The latter could occur as a consequence of regulation of relevant growth factors by such oncogenes. We therefore sought to determine whether EGFR or ErbB2/neu may contribute to tumor angiogenesis by examining their effects on the expression of vascular endothelial cell growth factor (VEGF)/vascular permeability factor (VPF), one of the most important of all known inducers of tumor angiogenesis. We found that in vitro tre},
added-at = {2010-02-05T11:28:39.000+0100},
author = {Petit, A. M. and Rak, J. and Hung, M. C. and Rockwell, P. and Goldstein, N. and Fendly, B. and Kerbel, R. S.},
biburl = {https://www.bibsonomy.org/bibtex/257882d572c298c5292023d1b0302f78c/kanefendt},
interhash = {09dc86438917b0402e35edc9031faf7a},
intrahash = {57882d572c298c5292023d1b0302f78c},
journal = {Am.J.Pathol.},
keywords = {A Adenocarcinoma Animals Antibodies Breast Carcinoma Cell Cells Cultured Dose-Response Down-Regulation Drug Endothelial Epidermal Expression Factor Factors Gene Growth Human Humans Immunoenzyme Lymphokines Mice Monoclonal Neoplasm Neoplasms Neoplastic Neovascularization Neutralization Nude Oncogenes Pathologic Proliferation Receptor Regulation Relationship Research Signal Squamous Survival Techniques Tests Transduction Transplantation Tumor Tyrosine Vascular blood cells drug effects erbB-2 immunology metabolism pathology pharmacology physiology protein therapy},
number = 6,
pages = {1523-1530},
timestamp = {2010-02-05T11:28:45.000+0100},
title = {Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors},
url = {PM:9403702},
volume = 151,
year = 1997
}